Phase II Study With Ocrelizumab Shows Significant Reduction In Disease Activity For Multiple Sclerosis Patients

 Ocrelizumab is a monoclonal immunosuppressant antibody targeting B-lymphocytes
Enhanced by Zemanta

No comments: